Lilly reports comparative data from ACHIEVE-3 and PIONEER PLUS studies

Data ReadoutFoundayoOral semaglutideNeutral

AI Analysis

Summary

Eli Lilly reported comparative data from ACHIEVE-3 and PIONEER PLUS studies analyzing its investigational therapy Foundayo against oral semaglutide in adults with type 2 diabetes. The article provides limited details on specific findings or clinical outcomes.

Clinical Trial Data

Outcome Details

Indirect treatment comparison data from ACHIEVE-3 and PIONEER PLUS studies

Importance:4/10

Sentiment:

0.00

Type 2 diabetesComparative analysisIndirect treatment comparison

Related Companies

$LLY

Read the original article

Published by Clinical Trials Arena on September 30, 2026 7:36 AM

Read Original